BRAF

Biomarkers

BRAF is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
v::BRAF	Rearrangement	1	1
BRAF rearrangements	Rearrangement	1	1
BRAF p.V600K	Somatic Variant	11	18
BRAF p.V600E	Somatic Variant	19	41

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BRAF p.V600K	Melanoma	Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Nivolumab	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Nivolumab	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Pembrolizumab	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Pembrolizumab	HC
Sensitivity (+)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib	HC
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Vemurafenib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA